Advocacy in Action

Endocrine Society Submits Testimony Urging Congress to Fund NIH, CDC, and Title X

The Endocrine Society continues to champion increases in funding for biomedical research. The Society submitted written testimony to the House Appropriations Committee for the FY 2025 Subcommittee Labor, Health and Human Services, Education, and Related Agencies bill to urge Congress to fund the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Title X at robust levels. The testimony urges Congress to fund the NIH at $51.303 billion, exclusive of additional funds to the Advanced Research Projects Agency for Health (ARPA-H), the CDC at $11.58 billion, and the Title X program at $512 million.

The testimony also emphasizes the importance of:

• Funding NIH consistently across all Institutes and Centers and urging for robust funding to avoid narrowing paylines
• Supporting women’s health research across the lifespan without limiting the scope of diseases that are studied
• Advancing research on anti-obesity medications such as GLP-1 agonists

Now is the time to reach out to your Members of Congress about the value of your research and research funding. We encourage you to take action in our online campaign to send messages to your Senators and Representatives today.

Society Meets with Food and Drug Administration to Discuss Access to Diabetes and Anti-Obesity Medications

This week, the Endocrine Society met with the Chief Medical Officer of the Food and Drug Administration (FDA) to discuss access to diabetes and anti-obesity medications (AOMs). In the last few months, the Society has heard from our members that they are experiencing limited availability for Ozempic, a GLP-1 agonist used to treat type-2 diabetes. While the FDA has reported that the Ozempic shortage has been resolved, it acknowledged there can be lag periods after a shortage ends. During the call, we also discussed insulin access because we have recently experiencedsome shortages of certain types of insulin. The Society pressed the FDA to provide more communication when shortages occur and what regions of the country are being impacted. We have also had conversations about GLP-1 shortages with Eli Lilly & Company and have reached out to Novo Nordisk about this issue. If you are currently experiencing a shortage of a GLP-1 medication, insulin, or other prescription medication, please contact [email protected].

Clinical Endocrinology Mentorship Opportunity at ENDO2024

The Endocrine Society will host the second annual Endocrinology Mentor Day (eMD) at ENDO 2024 in Boston. The event will take place on Sunday, June 2. During the event, medical students and residents will be paired with an Endocrine Society member as their “mentor” for the day. Mentors will guide attendees around ENDO and introduce them to ENDO’s signature programs, including poster presentations, interesting case studies, and a plenary session. The event at ENDO 2023 in Chicago last year was a big success, due in large part to our terrific mentors. If you are interested in joining us for this program as a mentor, or would like to learn more about the event, please email Ellie Cliff at [email protected].